Industry eyes revenue potential of next‑generation peptide drugs beyond GLP‑1
read at Endpoints ↗Neutral
The article notes that just a few years ago analysts were busy estimating the market size for GLP‑1 based weight‑loss medicines.
Today the conversation has shifted toward the commercial possibilities of other peptide therapies that could follow a similar path.
The piece, written by health‑tech correspondent Shelby Livingston, highlights the growing curiosity about how these newer peptides might generate future earnings for the sector.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Prepping for peptides”
read at Endpoints ↗76 words · retrieved Jun 18
comments(0)
5-min edit window · permanent after that